NCT06931652
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06931652
Title Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab (E-REVRI)
Acronym E-REVRI
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Lymphoma Academic Research Organisation
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Facility Status City State Zip Country Details
INSTITUT BERGONIE - Service d'Oncologie Médicale Bordeaux France Details
INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie Caen France Details
CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique Clermont-Ferrand France Details
CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang Lille France Details
CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie Marseille France Details
CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie Nancy France Details
GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie Paris France Details
HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique Paris France Details
CHU LYON-SUD - Hématologie Clinique Pierre-Bénite France Details
CHU PONTCHAILLOU - Hématologie Clinique Rennes France Details
INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie Saint-Cloud France Details
IUCT ONCOPOLE - Service Hématologie Toulouse France Details
CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire Tours France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field